以《中国药品综合评价指南参考大纲》为依据对达托霉素进行综合评价——安全性评价  

Comprehensive Evaluation of Daptomycin Based on the Guideline for Comprehensive Drug Evaluation in China-Safety Evaluation

作　　者：王江峰[1] 范辉[1] 马珂[1] 

机构地区：[1]浙江大学医学院附属邵逸夫医院药学部,浙江杭州310016

出　　处：《药品评价》2015年第18期12-18,32,共8页Drug Evaluation

摘　　要：《中国药品综合评价指南参考大纲》是尝试建立一套适合中国特色的,同时具有可操作性的药品综合评价体系,笔者所在的团队以2015年新发布的《中国药品综合评价指南参考大纲》(第二版)为依据,对目前唯一一种已上市的环脂肽类抗菌药物达托霉素进行了综合评价,一方面通过对《中国药品综合评价指南参考大纲》的具体实践来检验该指南的实际应用价值;另一方面为临床和社保部门提供适应我国国情的达托霉素的综合性评价信息。本文介绍的是达托霉素的安全性评价部分。Guideline for Comprehensive Drug Evaluation in China is an active attempt to establish a set of comprehensive drug evaluation system, which would fit in the domestic situation and be operative in China. The authors and their team members conducted the comprehensive evaluation of daptomycin, the only cyclic lipopeptide antibiotic on the market, according to new released Guideline for Comprehensive Drug Evaluation in China （2nd version, 2015）. The aim is to test the practical application values of this guideline through concrete practice, and expect to provide comprehensive evaluation information of daptomycin for clinical and social security departments as well. This article describes the safety evaluation of daptomycin.

关 键 词：药品 综合评价 达托霉素 安全性 

分 类 号：R969[医药卫生—药理学]